CD44-expression in human lung cancer cells and tumor tissue

Anja Wimmel(Philipps University of Marburg), Marcus Schuermann(Philipps University of Marburg), K. Havemann(Philipps University of Marburg), M. Schilli(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), D. Branscheid

Journal of Cancer Research and Clinical Oncology

January 1, 1995

10.1007/bf02572126

Cited by 0

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)

|Journal of Clinical Oncology|2005|654

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280

Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients

|Journal of Clinical Oncology|2008|235